ArticleScientific reports2025
Gut microbiota distinguishes aging hispanics with Alzheimer's disease: associations with cognitive impairment and severity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Gut Microbiota Dysbiosis and Neuroinflammation in Alzheimer's Disease: a Systematic Review of Mechanistic Insights.Molecular neurobiology · 2026Pooled it
- The correlation and gut microbial characteristics in the whole spectrum of Alzheimer's disease: a systematic review and meta-analysis.Frontiers in neuroscience · 2026Pooled it
- Gut Microbiome Changes in Preclinical Alzheimer's Disease.Nutrients · 2026Review
- Targeting the Gut-Brain Axis: Protective Effects of NMN in Alleviating D-Galactose-Induced Cognitive Deficits.Metabolites · 2026Article
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- Community Dynamics in a Changing World: highlights from the 1st Puerto Rico & Caribbean Microbiome Symposium and vision for a new microbiome hub.Sustainable microbiology · 2026Article
- Gut dysbiosis and systemic inflammation in elderly hypertensive patients with amnestic mild cognitive impairment.Frontiers in immunology · 2026Article
- Factors associated with cognitive developmental delay risk in 12-month-old infants.Frontiers in pediatrics · 2026Article
- Gut microbiota and gut-derived metabolites in defining multiple sclerosis phenotypic continuum.Frontiers in immunology · 2026Review
- Accelerated biological aging: the role of chronic inflammation, weathering and novel therapeutic strategies.Frontiers in aging · 2026Review
- Environmental exposures, microbiome dynamics and chronic disease risk in climate-vulnerable regions: interdisciplinary perspectives from Puerto Rico.Frontiers in public health · 2026Review
- Strengthening Integrative Microbiome Research Through Regional Leadership.International journal of environmental research and public health · 2025Article
- Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that begins with memory loss and can lead to death. In Puerto Rico, AD is the fourth leading cause of death, while in the United States, it ranks fifth. Research suggests the gut microbiome contributes to the pathophysiology of AD by promoting inflammation and amyloid buildup in the brain. This study examined the composition and diversity of the gut microbiota in Puerto Ricans with AD compared to controls and its relationship with cognitive impairment severity and APOE status. We recruited 100 participants (50 AD, 50 controls), who underwent clinical and cognitive assessments (MoCA/CDR). While overall microbial diversity and richness showed no significant differences, specific bacterial taxa exhibited subtle differential abundance. Faecalibacterium and Bacteroides were moderately significant and increased on controls compared to AD. Moreover, individuals carrying the APOE E4 allele exhibited lower abundances of butyrate-producing bacteria and an enrichment of potentially pro-inflammatory genera, including Eggerthella and Lachnoclostridium. These findings suggest that gut microbiota dysbiosis may contribute to cognitive decline and AD progression, highlighting the potential for microbiome-targeted therapeutic interventions in AD prevention and treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.